United Therapeutics (UTHR) Change in Accured Expenses (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Change in Accured Expenses data on file, last reported at -$12.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 388.46% year-over-year to -$12.7 million; the trailing twelve-month figure through Mar 2026 stood at $87.8 million (up 129.84% YoY), and the FY2025 full-year result was $97.9 million, up 129.27% from the prior year.
• Change in Accured Expenses eased to -$12.7 million in Q1 2026, from $23.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $46.1 million in Q2 2025 to a low of -$23.1 million in Q4 2023.
• A 5-year average of $13.5 million and a median of $22.3 million in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 228.89% in 2025 and tumbled 388.46% in 2026, its largest moves.
• Tracing UTHR's Change in Accured Expenses over 5 years: stood at $9.1 million in 2022, then slumped by 353.85% to -$23.1 million in 2023, then climbed by 22.08% to -$18.0 million in 2024, then soared by 228.89% to $23.2 million in 2025, then tumbled by 154.74% to -$12.7 million in 2026.
• Business Quant data shows UTHR's Change in Accured Expenses at -$12.7 million in Q1 2026, $23.2 million in Q4 2025, and $31.2 million in Q3 2025.